GlobeNewswire All Public CompaniesQwen · 实盘不做把握 9/10不做原因:不是事件
北京时间·🕒 发布 20:00:00·⟳ 抓取 20:00:55·⚡ 决策 08-27 20:02:04 +1m09s·61.1 天前
Alvotech宣布管理层将出席9月两场投资者会议（摩根士丹利全球医疗大会及德意志银行医疗峰会）
这是Alvotech管理层参加投资者会议的例行IR日历公告，不含任何新增产品审批、临床数据、财务指引变更、并购、合作或监管信息。投资者会议出席本身不构成股价催化剂，Web/KB/行情研究均不可能改变这一判断。
📄 原文GlobeNewswire All Public Companies↗ 原文
Alvotech to present at upcoming investor conferences in September
REYKJAVIK, ICELAND (August 27, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing i…
不做 Alvotech（ALVO.US）
例行投资者会议出席公告，不含任何新增基本面信息（无产品、临床、财务、合作或监管进展），不构成股价催化剂，无交易edge
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Alvotech于2026年8月27日发布新闻稿，宣布创始人兼董事长和首席战略官将于9月参加摩根士丹利全球医疗大会（炉边谈话）和德意志银行医疗峰会（投资者会议）。这是上市公司标准IR活动公告，不含任何新增基本面事实——无新产品、无临床数据、无财务指引、无合作协议、无监管进展。此类公告对股价无方向性影响，不构成可交易事件。
🔎 新鲜度:最早出现 2026-08-27 · 扩散 low · price-in 风险 low ↗
先例如何影响了这次决策
对本次决策的影响:无先例可用，事件本身不构成催化，无需先例校准
方向:无适用先例——投资者会议出席公告不构成可交易事件类型
涨幅量级:不适用
形态:不适用
工具执行结果 · 成功 1 · 降级 0 · 失败 0 · 取消 0
- fetch_decision_experience 成功 stock_tools HTTP · 861 ms
{
原文全文
展开原文 · 2,378 字
REYKJAVIK,
ICELAND (August 27, 2026)
— Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that Robert Wessman, Founder and Chairman, and Dr. Balaji V. Prasad, Chief Strategy Officer, will participate in the upcoming investor conferences in September as follows:
Morgan Stanley 24
th
Annual Global Healthcare Conference in New York –
Fireside chat on Tuesday, September 15, 2026 at 12:20 pm ET (16:20 GMT)
Deutsche Bank's 2026 Healthcare Summit in New York
–
Hosting investor meetings on Thursday, September 17, 2026.
A live webcast of the fireside chat will be available to the general public and can be accessed in the Investors Section of Alvotech's website under
Events and Presentations
. After the event, a recording will be available for replay for 90 days.
For further information, contact:
Media
Benedikt Stefansson
Sarah MacLeod
alvotech.media@alvotech.com
Investors
Dr. Balaji V Prasad
Benedikt Stefansson
Mikaela Vilchez
alvotech.ir@alvotech.com
About Alvotech
Alvotech is a biotechnology company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high-quality, cost-effective products and services, enabled by a fully integrated approach and broad in-house capabilities. Five biosimilars are already approved and marketed in multiple global markets, including biosimilars to Humira® (adalimumab), Stelara® (ustekinumab), Simponi® (golimumab), Eylea® (aflibercept) and Prolia®/Xgeva® (denosumab). The current development pipeline includes disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. For more information, please visit https://www.alvotech.com. None of the information on the Alvotech website shall be deemed part of this press release.
For more information, please visit our
website
or follow us on social media on
LinkedIn
,
Facebook
,
Instagram
, and
YouTube
.
ICELAND (August 27, 2026)
— Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that Robert Wessman, Founder and Chairman, and Dr. Balaji V. Prasad, Chief Strategy Officer, will participate in the upcoming investor conferences in September as follows:
Morgan Stanley 24
th
Annual Global Healthcare Conference in New York –
Fireside chat on Tuesday, September 15, 2026 at 12:20 pm ET (16:20 GMT)
Deutsche Bank's 2026 Healthcare Summit in New York
–
Hosting investor meetings on Thursday, September 17, 2026.
A live webcast of the fireside chat will be available to the general public and can be accessed in the Investors Section of Alvotech's website under
Events and Presentations
. After the event, a recording will be available for replay for 90 days.
For further information, contact:
Media
Benedikt Stefansson
Sarah MacLeod
alvotech.media@alvotech.com
Investors
Dr. Balaji V Prasad
Benedikt Stefansson
Mikaela Vilchez
alvotech.ir@alvotech.com
About Alvotech
Alvotech is a biotechnology company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high-quality, cost-effective products and services, enabled by a fully integrated approach and broad in-house capabilities. Five biosimilars are already approved and marketed in multiple global markets, including biosimilars to Humira® (adalimumab), Stelara® (ustekinumab), Simponi® (golimumab), Eylea® (aflibercept) and Prolia®/Xgeva® (denosumab). The current development pipeline includes disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. For more information, please visit https://www.alvotech.com. None of the information on the Alvotech website shall be deemed part of this press release.
For more information, please visit our
website
or follow us on social media on
,
,
, and
YouTube
.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。